LYL1

Across TCGA pan-cancer cohorts, LYL1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LYL1 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LYL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LYL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where LYL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.902	0.680	.009	16	view →
LUAD	DFS	Median	All	0.929	0.539	.013	6	view →
UCEC	OS	Quartile	All	0.922	1.000	.048	2	view →
CCRCC	DFS	Median	III,IV	0.774	0.207	.047	2	view →
LSCC	DFS	Median	All	0.574	0.815	.046	2	view →
PDAC	OS	Median	III,IV	0.378	0.727	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LYL1–HNSC (DFS)

Open the HNSC breakdown →